REG - MicroSalt PLC - Exercise of Stock Options and Total Voting Rights

MicroSaltAnnouncement

21/11/2025 15:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251121:nRSU6006Ia&default-theme=true

RNS Number : 6006I  MicroSalt PLC  21 November 2025

 

 

 

21 November 2025

 

MicroSalt plc

("MicroSalt®" or the "Company")

 

Exercise of Stock Options and Total Voting Rights

 

MicroSalt plc (AIM: SALT), a leading provider of full-flavour natural salt
with approximately 50% less sodium, announces that a total of 341,527 ordinary
shares of £0.001625 each in the capital of the Company ("Ordinary Shares")
("Option Shares") have been allotted to two shareholders to satisfy the
exercise of options over Ordinary Shares.

 

Options over an aggregate of 628,000 Ordinary Shares were exercised on a
cashless basis under option agreements entered into in December 2021 and
November 2022. Due to the cashless basis of the exercise a total of 341,527
Option Shares were allotted and issued. Pursuant to the terms of the option
agreements, the exercise prices of the Option Shares were US$0.25 and
US$0.545.

 

Application has been made to the London Stock Exchange for admission of the
Option Shares to trading on AIM ("Admission"). It is expected that Admission
will become effective on or around 26 November 2025.

 

Following the issue of the Option Shares, which on Admission will rank pari
passu with the existing Ordinary Shares, the total number of Ordinary Shares
in issue with voting rights in the Company will be 52,304,803. There are no
Ordinary Shares held in treasury.

 

The above figure of 52,304,803 may be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or change to their interest in, the
share capital of the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

Enquiries:

 

 MicroSalt plc                                    info@microsaltinc.com
 Rick Guiney (CEO)

 Zeus (Nominated Adviser and Broker)              +44 (0)20 3829 5000
 David Foreman / James Edis (Investment Banking)

 Gracechurch Group (Financial PR)                 +44 (0)20 4582 3500
 Heather Armstrong, Alexis Gore, Rebecca Scott

 

About MicroSalt

 

MicroSalt® is disrupting the global salt market with its patented,
full-flavour, low-sodium salt designed for both food manufacturers and
consumers. Using proprietary micron-sized particles, MicroSalt® delivers the
same salty taste as traditional salt with approximately 50% less sodium,
offering a scalable solution to one of the world's most pressing health
challenges. Year to date through 2025, MicroSalt® has contributed to more
than 634M servings made healthier.

 

Excess sodium consumption is a leading contributor to cardiovascular disease,
the world's number one cause of death. The World Health Organisation has
targeted a 30% reduction in global sodium intake by 2025, a shift projected to
save seven million lives by 2030. The economic case is equally compelling: in
the UK alone, cardiovascular disease costs £19 billion annually, and reducing
average daily salt intake by just one gram could save over 4,000 lives and
£288 million each year.

 

Operational since 2018, MicroSalt® has established a defensible IP portfolio,
holding a granted US patent and 14 pending applications worldwide. These
protections create significant barriers to entry in a market expected to grow
exponentially as regulation and consumer demand accelerate.

 

MicroSalt® is ideally positioned for scale and market leadership, with clear
pathways into food manufacturing, consumer channels, and ultimately the
broader £10+ billion global salt market. MicroSalt® is more than a healthier
alternative-it is a disruptive, category-defining solution poised to deliver
significant commercial and societal impact.

 

For more information, please visit www.microsaltinc.co or follow on X
@microSaltPLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRPKDBNPBDDODB



            Copyright 2019 Regulatory News Service, all rights reserved